Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

41.60
Delayed Data
As of Jan 13
 -0.24 / -0.57%
Today’s Change
31.38
Today|||52-Week Range
83.42
+11.11%
Year-to-Date
The Medicines Co LDL-Lowering Drug Positive in Phase II
Jan 09 / Zacks.com - Paid Partner Content
Here's Why Alnylam Pharmaceuticals Plunged 59.8% in 2016
Jan 07 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close41.84
Today’s open41.81
Day’s range41.32 - 43.39
Volume1,030,720
Average volume (3 months)1,494,258
Market cap$3.6B
Dividend yield--
Data as of 4:00pm ET, 01/13/2017

Growth & Valuation

Earnings growth (last year)+28.87%
Earnings growth (this year)-40.53%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-18.72%
P/E ratioNM
Price/Sales192.40
Price/Book2.80

Competitors

 Today’s
change
Today’s
% change
ACADACADIA Pharmaceutica...-0.01-0.03%
CTLTCatalent Inc+0.21+0.80%
GLPGGalapagos NV+0.72+1.05%
AGNPRAAllergan plc+1.26+0.16%
Data as of 4:02pm ET, 01/13/2017

Financials

Next reporting dateFebruary 16, 2017
EPS forecast (this quarter)-$1.32
Annual revenue (last year)$41.1M
Annual profit (last year)-$290.1M
Net profit margin-705.83%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts


Search for Jobs